Sana Biotechnology, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Sana Biotechnology, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $186.00K, a 0.54% increase year-over-year.
- Sana Biotechnology, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $185.00K, a 82.82% decline year-over-year.
- Sana Biotechnology, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $1.08M, a 36.83% decline year-over-year.
- Sana Biotechnology, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $1.71M, a 69.15% increase year-over-year.
- Sana Biotechnology, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $350.00K, a 76.85% decline from fiscal 2024.
- Sana Biotechnology, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $1.51M, a 41.98% decline from fiscal 2023.
- Sana Biotechnology, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $2.61M, a 26.63% increase from fiscal 2022.
- Sana Biotechnology, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $2.06M, a 5.55% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $186.00K 10-Q · filed 2026-08-10 | |
| 2025-12-31 | $350.00K 10-K · filed 2026-03-03 | |
| 2025-06-30 | $185.00K 10-Q · filed 2026-08-10 | |
| 2024-12-31 | $1.51M 10-K · filed 2026-03-03 | |
| 2024-06-30 | $1.08M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $2.61M 10-K · filed 2026-03-03 | |
| 2023-06-30 | $1.71M 10-Q · filed 2024-11-08 | |
| 2022-12-31 | $2.06M 10-K · filed 2025-03-17 | |
| 2022-06-30 | $1.01M 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $2.18M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |